Telomir Pharmaceuticals, INC 8-K filings

Telomir Pharmaceuticals announces the immediate resignation of its General Counsel and Board member, Christos Nicholoudis, effective April 10, 2024.

Telomir Pharmaceuticals successfully closed its initial public offering, raising $7 million before expenses, and began trading on the Nasdaq Capital Market under the ticker symbol TELO.